Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Lancet Gastroenterol Hepatol. 2021 Oct 22;6(12):1002–1014. doi: 10.1016/S2468-1253(21)00312-5

Figure 5.

Figure 5.

Comparative safety of biologic agents for risk of serious adverse events and any infections in patients with moderate-to-severe Crohn’s disease, using network meta-analysis, expressed as odds ratios with 95% confidence intervals. Comparisons read from left-to-right; odds ratios for comparisons in the cell in common between column- and row-defining treatment. For serious adverse events, odds ratio <1 favors row-defining treatment. For risk of infections, odds ratio <1 favors column-defining treatment.